CO3_2019

24 ChimicaOggi - Chemistry Today - vol. 37(3) May/June 2019 Ulrich Wietelmann , Manager Business Development & Innovations Lithium Specialties and Battery Materials - Albemarle Boris Gorin , Senior Scientific Advisor, Research & Development Alphora Research Jacopo Buzzanca , Custom Synthesis BD Angelini SpA | Fine Chemicals Division Paul Quigley , Head of Drug Substance and Samuel Bourne , Process Development Chemist - Arcinova Miguel Angel Gonzalez , Sr. Director – Chemical Engineering Asymchem Marcel Vranceanu , Research Engineer Formulation Processing Technologies and Christian Holtze , Senior Research Engineer Formulation Technology - BASF Franz Amann , Senior Scientist - Carbogen Amcis Charlotte Wiles , CEO - Chemtrix Guillaume Gauron , EMEA Technical Sales Manager Corning ® Advanced-Flow™ Reactors John Tsanaktsidis , Research Director - CSIRO Manufacturing Tony Warr , Head of Process Technology Dr. Reddy’s Laboratories Jochen Becker , Global Project Manager Evonik Nutrition & Care PANELISTS Ulrich Wietelmann , Manager Business Development & Innovations Lithium Specialties and Battery Materials - Albemarle Finally, there are yields improvements, better product purities, a higher degree of process stability and reduced solvent utilization possible. All these advantages have been recognized by the industry and pharma processes are currently converting from batch to flow in a high rate. The US FDA (Federal Drug Administration) has recognized the strong impact of continuous manufacturing on product quality and therefore supports the conversion from batch to flow. Novartis expects that continuous manufacturing in the pharmaceutical industry has the potential to cut drug manufacturing time by 90% and drug manufacturing costs by 30-50%. (https://www.novartis.com/stories/discovery/ new-drug-manufacturing-tools-change-pharma-chemistry). As an example, we have found that butyllithium processes (bromo/lithium exchange and deprotonations) are significantly improved by simply using butyllithium in higher concentration (> 2.5 mol/L). Why change from batch to flow? Flow chemistry serves to achieve process intensification and it is an efficient tool to implement green chemistry principles. Frequently, the reaction concentration can be increased and higher room/time yield be achieved hence. Besides process intensification, there are safety advantages for the case of toxic or thermally labile materials involved and/or high exothermicity of the reaction. Energy savings are realized due to less specific cooling needs. Panel Discussion on FLOW CHEMISTRY In this issue, we present a Panel Discussion on manufacturing using flow chemistry . This topic is of particular interest as the importance of micro reactor technology and flow chemistry in industrial manufacturing is rapidly rising; we have testimony of this because of the high number of companies that showed willingness to participate in this discussion around a virtual table. The following players have joined the initiative: Torfinn Haaland , Research Coordinator - GE Healthcare Flavien Susanne , R&D Drug Substance Continuous Processing Lead - GSK Silvia Werner , Project manager Heraeus Pharmaceutical Ingredients Rui Loureiro , Director, R&D Process Chemistry Development Hovione Steve Pollington , Research Leader - Johnson Matthey Pierre Giuliano , Managing Director - La Mesta - Yriel Group Rajiv Khatau , Managing Director - LODAAT Amanda Evans , Scientist - Los Alamos National Laboratory Dirk Kirschneck , Managing Director - Microinnova Steven T. Perry , Senior Product Manager Parr Instrument Company Ryan Seongho Oh , Vice President, Head of R&D - SK Biotek Matthew M. Bio , President & CEO - Snapdragon Chemistry Frank Gupton , Department Chair Virginia Commonwealth University

RkJQdWJsaXNoZXIy MTY5Njg=